Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

CANCER GENOMICS

Predicting progression to AML

Nature Medicine volume 24, pages 904–906 (2018)Cite this article

Subjects

The number, identity, and burden of mutations in clonal hematopoiesis are associated with the risk and timing of progression to acute myeloid leukemia.

Acute myeloid leukemia (AML) is an aggressive malignancy characterized by clonal expansion of undifferentiated myeloid precursors that results in impaired hematopoiesis and bone marrow failure. Recent studies of clonal hematopoiesis, an expansion of blood cells derived from a single hematopoietic stem cell, indicate that for some individuals, clonal hematopoiesis is a premalignant state that may be identified many years before the development of AML or another hematological malignancy. Because of increasingly sensitive methods of detection, it may be possible to identify clonal hematopoiesis within all individuals as time progresses1. Therefore, it is important to identify clonal hematopoiesis that is of clinical significance rather than a potentially benign aspect of aging.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The risk of developing AML.

References

  1. Young, A. L., Challen, G. A., Birmann, B. M. & Druley, T. E. Nat. Commun. 7, 12484 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Steensma, D. P. et al. Blood 126, 9–16 (2015).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Genovese, G. et al. N. Engl. J. Med. 371, 2477–2487 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Jaiswal, S. et al. N. Engl. J. Med. 371, 2488–2498 (2014).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Jaiswal, S. et al. N. Engl. J. Med. 377, 111–121 (2017).

    Article  PubMed  Google Scholar 

  6. Abelson, S. et al. Nature https://doi.org/10.1038/s41586-018-0317-6 (2018).

  7. Desai, P. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0081-z (2018).

  8. Papaemmanuil, E. et al. N. Engl. J. Med. 374, 2209–2221 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Amatangelo, M. D. et al. Blood 130, 732–741 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Lee, S. C. & Abdel-Wahab, O. Nat. Med. 22, 976–986 (2016).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Agathocleous, M. et al. Nature 549, 476–481 (2017).

    PubMed  PubMed Central  Google Scholar 

  12. Cimmino, L. et al. Cell 170, 1079–1095 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brigham and Women’s Hospital, Boston, MA, USA

    Rob S. Sellar & Benjamin L. Ebert

  2. Broad Institute of MIT and Harvard, Cambridge, MA, USA

    Rob S. Sellar & Benjamin L. Ebert

  3. UCL Cancer Institute, University College London, London, UK

    Rob S. Sellar

  4. Department of Pathology, Stanford University, Stanford, CA, USA

    Siddhartha Jaiswal

  5. Dana-Farber Cancer Institute, Boston, MA, USA

    Benjamin L. Ebert

Authors
  1. Rob S. Sellar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siddhartha Jaiswal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Benjamin L. Ebert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Benjamin L. Ebert.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sellar, R.S., Jaiswal, S. & Ebert, B.L. Predicting progression to AML. Nat Med 24, 904–906 (2018). https://doi.org/10.1038/s41591-018-0114-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-018-0114-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer